Gisella Terre'Blanche

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/280474/publications.pdf

Version: 2024-02-01

687363 713466 37 522 13 21 citations h-index g-index papers 38 38 38 650 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Inhibition of monoamine oxidase B by selected benzimidazole and caffeine analogues. Bioorganic and Medicinal Chemistry, 2007, 15, 3692-3702.	3.0	67
2	Physicochemical prediction of a brain–blood distribution profile in polycyclic amines. Bioorganic and Medicinal Chemistry, 2003, 11, 3569-3578.	3.0	38
3	1,3,7-Triethyl-substituted xanthinesâ€"possess nanomolar affinity for the adenosine A1 receptor. Bioorganic and Medicinal Chemistry, 2015, 23, 6641-6649.	3.0	36
4	Screening of novel pentacyclo-undecylamines for neuroprotective activity. European Journal of Pharmacology, 2003, 458, 73-79.	3. 5	32
5	Thio- and aminocaffeine analogues as inhibitors of human monoamine oxidase. Bioorganic and Medicinal Chemistry, 2011, 19, 7507-7518.	3.0	29
6	Structure–activity relationships in the inhibition of monoamine oxidase B by 1-methyl-3-phenylpyrroles. Bioorganic and Medicinal Chemistry, 2008, 16, 2463-2472.	3.0	26
7	The adenosine A2A antagonistic properties of selected C8-substituted xanthines. Bioorganic Chemistry, 2013, 49, 49-58.	4.1	26
8	2-Aminopyrimidines as dual adenosine A1/A2A antagonists. European Journal of Medicinal Chemistry, 2015, 104, 177-188.	5.5	25
9	Inhibition of monoamine oxidase B by N-methyl-2-phenylmaleimides. Bioorganic and Medicinal Chemistry, 2009, 17, 3104-3110.	3.0	18
10	Evaluation of 2â€benzylideneâ€1â€tetralone derivatives as antagonists of A ₁ and A _{2A} adenosine receptors. Chemical Biology and Drug Design, 2018, 91, 234-244.	3.2	18
11	The adenosine receptor affinities and monoamine oxidase B inhibitory properties of sulfanylphthalimide analogues. Bioorganic Chemistry, 2015, 59, 117-123.	4.1	16
12	Imidazo $[1,2-\hat{l}\pm]$ pyridines possess adenosine A1 receptor affinity for the potential treatment of cognition in neurological disorders. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 3963-3967.	2.2	15
13	Methoxy substituted 2-benzylidene-1-indanone derivatives as A ₁ and/or A _{2A} AR antagonists for the potential treatment of neurological conditions. MedChemComm, 2019, 10, 300-309.	3.4	14
14	Benzopyrone represents a privilege scaffold to identify novel adenosine A1/A2A receptor antagonists. Bioorganic Chemistry, 2018, 77, 136-143.	4.1	13
15	Carbamate substituted 2-amino-4,6-diphenylpyrimidines as adenosine receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 734-738.	2.2	12
16	Treatment of an adrenomyeloneuropathy patient with Lorenzo's oil and supplementation with docosahexaenoic acid-A case report. Lipids in Health and Disease, 2011, 10, 152.	3.0	11
17	Discovery of 1,3-diethyl-7-methyl-8-(phenoxymethyl)-xanthine derivatives as novel adenosine A 1 and A 2 A receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 5951-5955.	2.2	11
18	2–Benzylidene–1–Indanone Analogues as Dual Adenosine A1/A2a Receptor Antagonists for the Potential Treatment of Neurological Conditions. Drug Research, 2019, 69, 382-391.	1.7	11

#	Article	IF	CITATIONS
19	Sulfanylphthalonitrile analogues as selective and potent inhibitors of monoamine oxidase B. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 7367-7370.	2.2	10
20	Investigating the potential neuroprotective effects of statins on DNA damage in mouse striatum. Food and Chemical Toxicology, 2008, 46, 3186-3192.	3.6	9
21	The Styrene Metabolite, Phenylglyoxylic Acid, Induces Striatal-Motor Toxicity in the Rat: Influence of Dose Escalation/Reduction over Time. Neurotoxicity Research, 2011, 20, 97-101.	2.7	9
22	Benzyloxynitrostyrene analogues – A novel class of selective and highly potent inhibitors of monoamine oxidase B. European Journal of Medicinal Chemistry, 2017, 125, 1193-1199.	5.5	9
23	C2-substituted quinazolinone derivatives exhibit A1 and/or A2A adenosine receptor affinities in the low micromolar range. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127274.	2.2	9
24	C3 amino-substituted chalcone derivative with selective adenosine rA1 receptor affinity in the micromolar range. Chemical Papers, 2021, 75, 1581-1605.	2.2	8
25	Neurotoxicity studies with the monoamine oxidase B substrate 1-methyl-3-phenyl-3-pyrroline. Life Sciences, 2007, 81, 458-467.	4.3	6
26	Novel sulfanylphthalimide analogues as highly potent inhibitors of monoamine oxidase B. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 6632-6635.	2.2	6
27	Synthesis and evaluation of methoxy substituted 2-benzoyl-1-benzofuran derivatives as lead compounds for the development adenosine A1 and/or A2A receptor antagonists. Bioorganic Chemistry, 2020, 94, 103459.	4.1	6
28	Synthesis and Structure Activity Relationships of Chalcone based Benzocycloalkanone Derivatives as Adenosine A1 and/or A2A Receptor Antagonists. Drug Research, 2020, 70, 243-256.	1.7	6
29	Interactions of 1-methyl-3-phenylpyrrolidine and 3-methyl-1-phenyl-3-azabicyclo[3.1.0]hexane with monoamine oxidase B. Bioorganic and Medicinal Chemistry, 2010, 18, 4111-4118.	3.0	5
30	Therapeutic potentials of agonist and antagonist of adenosine receptors in type 2 diabetes. Reviews in Endocrine and Metabolic Disorders, 2021, 22, 1073-1090.	5.7	5
31	Paracetamol prevents hyperglycinemia in vervet monkeys treated with valproate. Metabolic Brain Disease, 2012, 27, 327-335.	2.9	4
32	Deuterium isotope effects for the oxidation of 1-methyl-3-phenyl-3-pyrrolinyl analogues by monoamine oxidase B. Bioorganic and Medicinal Chemistry, 2008, 16, 8813-8817.	3.0	3
33	Exploration of chalcones and related heterocycle compounds as ligands of adenosine receptors: therapeutics development. Molecular Diversity, 2022, 26, 1779-1821.	3.9	3
34	Design, synthesis and evaluation of amino-3,5-dicyanopyridines and thieno[2,3-b]pyridines as ligands of adenosine A1 receptors for the potential treatment of epilepsy. Medicinal Chemistry Research, 2022, 31, 1277-1297.	2.4	3
35	8-(3-phenylpropyl)-1,3,7-triethylxanthine is a synthetic caffeine substitute with stronger metabolic modulator activity. Toxicology in Vitro, 2018, 53, 114-120.	2.4	2
36	New fused pyrroles with rA1/A2A antagonistic activity as potential therapeutics for neurodegenerative disorders. Molecular Diversity, 2022, 26, 2211-2220.	3.9	1

#	Article	IF	CITATIONS
37	Chalconeâ€inspired <i>r</i> A ₁ /A _{2A} adenosine receptor ligands: Ring closure as an alternative to a reactive substructure. Chemical Biology and Drug Design, 2022, 99, 416-437.	3.2	O